Sale!

Selank

In stock

$43.98$46.99

Concentration
5 mg per vial
Purchase this product now and earn 44 Points!

This product is prepared for LABORATORY RESEARCH USE ONLY and may not be used for other purposes.

-
+

Free & Fast
Shipping

Earn
Rewards

Excellent
Service

Properties

Molecular Formula C33H57N11O9
Molecular Weight 751.9
Monoisotopic Mass 751.43407244
Polar Area 322
Complexity 1360
XLogP -6.1
Heavy Atom Count 53
Hydrogen Bond Donor Count 9
Hydrogen Bond Acceptor Count 12
Rotatable Bond Count 19
Physical Appearance Fine White Lyophilized Powder
Stability Lyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS Selank Laboratory Chemical Safety Summary

Identifiers

CID 11765600
CAS 129954-34-3
InChI InChI=1S/C33H57N11O9/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53/h19-24, 26, 45H, 2-18, 34-35H2, 1H3, (H, 39, 47)(H, 40, 48)(H, 41, 49)(H, 52, 53)(H4, 36, 37, 38)/t19-, 20+, 21+, 22+, 23+, 24+, 26+/m1/s1
InChIKey JTDTXGMXNXBGBZ-YVHUGQOKSA-N
Isomeric SMILES C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(=O)O)N)O
Canonical SMILES CC(C(C(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)N2CCCC2C(=O)NCC(=O)N3CCCC3C(=O)O)N)O
IUPAC Name (2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S, 3R)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid

2D Structure

Generated by Extreme Peptide with Open Babel, version 2.3.1, http://openbabel.org (accessed June 28, 2022)

Selank 2D molecular structure vector generated with oBabel

Description

Selank is a 7 amino acid synthetic analogue of the naturally occurring tetrapeptide ‘tuftsin’1. Selank is considered to be a nootropic substance – something that improves one or more aspects of cognitive function, like memory, motivation, and attention2. Selank acts as a regulator of serotonin and monoamine neurotransmitters, which is typical of many anti-anxiety medications – something Selank was first developed to be3. With further research, Selank was found to increase mental focus and calmness4 in animal test subjects, along with having positive anxiolytic and anti-depressant properties.

Nootrope and Anti-Anxiety Agent

Selank shows great potential as an agent to reduce anxiety side effects5 in patients undergoing necessary steroidal or androgenic treatments for conditions like muscular dystrophy. Animal trials have demonstrated that Selank alleviates symptoms of anxiety, of excess excitability, and of anhedonia6 – the inability to feel pleasure – replacing them with the nootropic effects of mental alertness, motivation, and a sense of general well being. It has been suggested that this combination of therapeutic action would be desirable to apply in the recovery treatment of drug users, who may experience anxiety, depression, and anhedonia as well7.

Product Comparison

Many anti-anxiety or anti-depressant drugs, like benzodiazapines, for example, have a sedative effect8. Animal trials with Selank have demonstrated that this agent is not only effective in stabilizing mood and avoiding anxiety, but also improves motivation, reduces mental fatigue, and leads to a sense of mental sharpness. Also unlike most anti-anxiety or anti-depressant drugs, Selank is reported to have no tendency of inducing dependence or withdrawal symptoms9.

Synonyms:

Selank, Selax, Semax, Tuftsin Analogue


Peer-Reviewed Sources:

  1. Semenova, T. P., Zakharova, N. M., & Kozlovskaia, M. M. (2008). [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. Eksperimental’naia i klinicheskaia farmakologiia, 72(4), 6-8. ↩︎
  2. Semenova, T. P., Kozlovskiĭ, I. I., Zakharova, N. M., & Kozlovskaia, M. M. (2010). [Experimental optimization of learning and memory processes by selank]. Eksperimental’naia i klinicheskaia farmakologiia, 73(8), 2-5. ↩︎
  3. Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., & Smulevich, A. B. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine, 131(4), 315-317. ↩︎
  4. Sollertinskaya, T. N., Shorokhov, M. V., Kozlovskaya, M. M., Kozlovskii, I. I., & Sudakov, K. V. (2008). Compensatory and antiamnestic effects of heptapeptide Selank in monkeys. Journal of Evolutionary Biochemistry and Physiology, 44(3), 332-340. ↩︎
  5. Kozlovskaya, M. M., Kozlovskii, I. I., Val’dman, E. A., & Seredenin, S. B. (2003). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and behavioral physiology, 33(9), 853-860. ↩︎
  6. Sarkisova, K., Kozlovskiĭ, I. I., & Kozlovskaia, M. M. (2007). [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]. Zhurnal vysshei nervnoi deiatelnosti imeni IP Pavlova, 58(2), 226-237. ↩︎
  7. Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O., … & Seredenin, S. B. (2007). [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov, 108(4), 38-48. ↩︎
  8. Weitzel, K. W., Wickman, J. M., Augustin, S. G., & Strom, J. G. (2000). Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clinical therapeutics, 22(11), 1254-1267. ↩︎
  9. Kolik, L. G., Nadorova, A. V., & Kozlovskaya, M. M. (2014). Efficacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation. Bulletin of experimental biology and medicine, 157(1), 52-55. ↩︎

All literature, information, and data, provided on this website are for informational and educational purposes only.

Accurate research is our priority.

Same Day Shipping
We offer same day shipping on all orders of in stock items placed before 12:00pm EST.
Dedicated Service
Our team is readily available to assist with all of your customer service requests.
Free Shipping
We've got you covered! Free shipping is available on any order over $50.
Earn Rewards
Earn points every time you buy from us and use them towards future orders!
Extreme Peptide vial with logo and indicators